BMT Diagnostics
Product/ Company Information:
The company was founded in 2004 and has been active in developing, manufacturing and
marketing rapid diagnostic tests (RDT) in Israel and abroad base on PATENTS-NO STEP
(StrepA-Covid 19 Ag (sample from throat)-Influeanza A+B), etc.
Focused initially on introducing rapid diagnostic tests to pharmacies and health
maintenance organizations (HMO) for self and professional testing, the company has led
the adoption of Strep A RDT as a firstline screening tool by physicians and patients. This
has created a new market opportunity, opening the door to additional tests that bridge the
patient-physician chasm.
Over the last two decades there has been a significant market shift in extending medical
testing from hospitals’ laboratories to Point-of-Care (POC) physician office/clinic settings
and to private homes (e.g. pregnancy tests and glucose tests). However, most RDT
(excluding glucose tests) are still predominantly performed in hospitals and by POC
professionals, since standard tests and kits have yet to overcome the regulatory challenges
associated with developing a user-friendly product that will widely appeal to healthconscious consumers.
The company has pioneered a first of its kind, simple-to-use, integrated device for Strep ACOVID19 &Influenza A+B testing under its Lab-On-Time Trade Mark. It is in the process of
developing additional swab-based tests based on its Lab-On-Time™ platform. It has one
international patent application covering its core swab-based integrated sampling and
testing device platform.
After receiving validation and establishing a credible foothold in the European market, the
company will begin to expand into the USA and other territories.
Interested in doing business in: Philippines
Activity: Rapid Diagnostics Test- based on PATENT- NO STEP
